GALECTIN THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.52 USD | +5.88% |
|
+6.33% | +51.81% |
| Jul. 01 | Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Value Index | CI |
| Jul. 01 | Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 162.7 | 127.9 | 122.8 | 67.15 | 102.7 | 147.9 | - | - |
| Enterprise Value (EV) 1 | 162.7 | 127.9 | 122.8 | 67.15 | 102.7 | 147.9 | 147.9 | 147.9 |
| P/E ratio | -7.33 x | -5.46 x | -3.98 x | -1.74 x | -2.24 x | -3.61 x | -1.5 x | -2.45 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 4.07 x | 0.82 x |
| EV / Revenue | - | - | - | - | - | - | 4.07 x | 0.82 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -14,997,615 x | - | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 56,886 | 57,077 | 59,341 | 59,426 | 61,849 | 62,148 | - | - |
| Reference price 2 | 2.860 | 2.240 | 2.070 | 1.130 | 1.660 | 2.380 | 2.380 | 2.380 |
| Announcement Date | 3/16/20 | 3/31/21 | 3/31/22 | 3/30/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 36.32 | 179.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -13.44 | -23.44 | -30.18 | -38.35 | -38.07 | -41.2 | -101.5 | -63.4 |
| Operating Margin | - | - | - | - | - | - | -279.56% | -35.28% |
| Earnings before Tax (EBT) 1 | -13.29 | -23.46 | -30.53 | -38.78 | -41.07 | -40.72 | -101.4 | -63.3 |
| Net income 1 | -20.18 | -23.6 | -30.7 | -38.87 | -44.8 | -40.98 | -101.4 | -63.3 |
| Net margin | - | - | - | - | - | - | -279.28% | -35.23% |
| EPS 2 | -0.3900 | -0.4100 | -0.5200 | -0.6500 | -0.7400 | -0.6600 | -1.590 | -0.9700 |
| Free Cash Flow | -10.85 | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/31/21 | 3/31/22 | 3/30/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.425 | -9.935 | -9.662 | -8.122 | -10.63 | -10.34 | -9.003 | -9.166 | -9.561 | -9.648 | -10.1 | -10.5 | -10.5 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.221 | -9.932 | -9.613 | -8.597 | -10.63 | -11.53 | -9.114 | -10.43 | -9.997 | -11.49 | -9.975 | -10.38 | -10.38 |
| Net income 1 | -7.288 | -9.916 | -9.677 | -8.581 | -10.7 | -11.53 | -9.177 | -14.04 | -10.06 | -11.5 | -10.04 | -10.45 | -10.45 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1200 | -0.1700 | -0.1600 | -0.1400 | -0.1800 | -0.1900 | -0.1500 | -0.2400 | -0.1600 | -0.1900 | -0.1600 | -0.1700 | -0.1700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/29/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -10.8 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/31/21 | 3/31/22 | 3/30/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.38
USD
Average target price
11
USD
Spread / Average Target
+362.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.37% | 148M | |
| +22.15% | 46.56B | |
| +45.32% | 41.67B | |
| -2.37% | 41.16B | |
| +33.84% | 32.4B | |
| -6.35% | 28.1B | |
| +20.42% | 28.18B | |
| +48.83% | 14.52B | |
| +45.00% | 13.74B | |
| +0.06% | 12.17B |
- Stock Market
- Equities
- GALT Stock
- Financials Galectin Therapeutics Inc.
